Millendo Therapeutics, Inc. (MLND:NASDAQ) Investor Relations Material

Overview

Millendo Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of new treatments for endocrine diseases with significant unmet medical needs. The company's primary focus is on creating distinct and transformative treatments where current therapies are insufficient. Millendo is currently working on advancing its lead candidate drug, MLE-301, for the treatment of vasomotor symptoms in women experiencing menopause.

Frequently Asked Questions

What is Millendo Therapeutics, Inc.'s ticker?

Millendo Therapeutics, Inc.'s ticker is MLND

What exchange is Millendo Therapeutics, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Millendo Therapeutics, Inc.'s headquarters?

They are based in Ann Arbor, Michigan

How many employees does Millendo Therapeutics, Inc. have?

There are 11-50 employees working at Millendo Therapeutics, Inc.

What is Millendo Therapeutics, Inc.'s website?

It is https://millendo.com/

What type of sector is Millendo Therapeutics, Inc.?

Millendo Therapeutics, Inc. is in the Healthcare sector

What type of industry is Millendo Therapeutics, Inc.?

Millendo Therapeutics, Inc. is in the Biotechnology industry

Who are Millendo Therapeutics, Inc.'s peers and competitors?

The following five companies are Millendo Therapeutics, Inc.'s industry peers:

- TCR2 Therapeutics Inc.

- Crinetics Pharmaceuticals

- Incyte

- Anika Therapeutics

- Cara Therapeutics